FrancophonIA/ELRC3.0 huggingface dataset:
English: Gastrointestinal disorders very common diarrhoea common vomiting, nausea, abdominal pain, abdominal distension, dyspepsia, flatulence uncommon pancreatitis acute, pancreatic enzymes increased
Icelandic: Meltingarfæri mjög algengar niðurgangur algengar uppköst, ógleði, kviðverkir, uppþemba, meltingartruflun, vindgangur sjaldgæfar bráð brisbólga, hækkun brisensíma
English: Symtuza can be co-administered with H2-receptor antagonists without dose adjustments.
Icelandic: Nota má Symtuza samhliða H2-viðtakablokkum án þess að breyta þurfi skömmtum.
English: Symtuza 800 mg/150 mg/200 mg/10 mg tablets darunavir/cobicistat/emtricitabine/tenofovir alafenamide
Icelandic: Symtuza 800 mg/150 mg/200 mg/10 mg töflur darunavir/cobicistat/emtricitabin/tenofovir alafenamíð
English: Caution should be exercised when combining one of these anti-neoplastic agents with Symtuza.
Icelandic: Gæta skal varúðar þegar eitt þessara æxlishemjandi lyfja er gefið samhliða Symtuza.
English: When used for birth control, non-hormonal contraception methods are recommended.
Icelandic: Þegar um getnaðarvarnarlyf er að ræða er ráðlagt að nota getnaðarvarnir sem ekki innihalda hormón.
English: Clinical monitoring is recommended when co-administering Symtuza with clonazepam.
Icelandic: Mælt er með klínísku eftirliti við samhliða notkun Symtuza og clonazepams.
English: Cobicistat is not expected to inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9 or CYP2C19.
Icelandic: Ekki er búist við að cobicistat hamli CYP1A2, CYP2B6, CYP2C8, CYP2C9 eða CYP2C19.
English: Based on theoretical considerations
Icelandic: Byggt á takmarkaðri reynslu virðist
English: Inflammation of the pancreas (pancreatitis) has been reported in up to 1 patient in 100.
Icelandic: Greint var frá bólgu í brisi hjá allt að 1 af hverjum 100 sjúklingum.
English: Clinical monitoring is recommended when co-administering Symtuza with these analgesics.
Icelandic: Mælt er með klínísku eftirliti þegar Symtuza er gefið samhliða þessum verkjalyfjum.
English: Based on theoretical considerations co-administration of DRV/COBI with dabigatran or ticagrelor may increase concentrations of the anticoagulant.
Icelandic: Byggt á fræðilegum athugunum getur samhliða notkun DRV/COBI með dabigatrani eða ticagrelori aukið þéttni segavarnarlyfsins.
English: The combination may result in increased risk of cardiovascular adverse events with salmeterol, including QT prolongation, palpitations and sinus tachycardia.
Icelandic: Samsetningin getur aukið hættuna á aukaverkunum af völdum salmeterols á hjarta og æðakerfi, þ.m.t. lengingu á
English: If you have chronic hepatitis B or C infection, your doctor should check your blood tests more often because you have an increased chance of developing liver problems.
Icelandic: Læknirinn ætti að láta framkvæma blóðpróf oftar ef þú ert með langvinna lifrarbólgu
English: Based on theoretical considerations clarithromycin is expected to increase darunavir and/or cobicistat plasma concentrations.
Icelandic: Byggt á fræðilegum athugunum er búist við að clarithromycin auki plasmaþéttni darunavirs og/eða cobicistats.
English: The combination of colchicine and Symtuza is contraindicated in patients with renal or hepatic impairment (see section 4.3).
Icelandic: Ekki má nota colchicin samhliða Symtuza hjá sjúklingum með skerta nýrna- eða lifrarstarfsemi (sjá kafla 4.3).
English: In vitro, tenofovir alafenamide is not metabolised by CYP1A2, CYP2C8, CYP2C9, CYP2C19, or CYP2D6.
Icelandic: In vitro umbrotnar tenofovir alafenamíð ekki fyrir tilstilli CYP1A2, CYP2C8, CYP2C9, CYP2C19 eða CYP2D6.
English: Based on stratum adjusted MH test where stratification factors are HIV-1 RNA level (≤ 100,000 or > 100,000 copies/mL) and CD4+ cell count (< 200 or ≥ 200 cells/µL).
Icelandic: RNA gildi (≤ 100,000 eða > 100,000 eintök/ml) og CD4+ frumutalning (< 200 eða ≥ 200 frumur/µl).
English: Based on theoretical considerations DRV/COBI is expected to increase digoxin plasma concentrations.
Icelandic: Byggt á fræðilegum athugunum er búist við að DRV/COBI auki plasmaþéttni digoxins.
English: These interactions are described in the interaction table below.
Icelandic: Þessum milliverkunum er lýst í milliverkanatöflunni hér á eftir.
English: Emerging resistance in HIV-1 infected, treatment-naïve and virologically suppressed patients
Icelandic: Nýframkomið ónæmi hjá sjúklingum sem eru sýktir af HIV-1 og hafa ekki áður fengið meðferð og eru veirufræðilega bældir
English: Based on theoretical considerations, no mechanistic interaction is expected.
Icelandic: Byggt á fræðilegum athugunum er ekki búist við milliverkunum í tengslum við verkunarmáta.
English: Hepatobiliary disorders common hepatic enzyme increased uncommon acute hepatitis a, cytolytic hepatitis
Icelandic: Lifur og gall algengar hækkuð gildi lifrarensíma sjaldgæfar bráð lifrarbólga a, frumueyðandi lifrarbólga (cytolytic hepatitis)
English: Unlike ritonavir, cobicistat is not an inducer of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or UGT1A1.
Icelandic: Ólíkt ritonaviri er cobicistat ekki virkir fyrir CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 eða UGT1A1.
English: No clinically relevant pharmacokinetic differences due to gender have been identified for cobicistat, emtricitabine or tenofovir alafenamide.
Icelandic: Klínískt marktækur munur á lyfjahvörfum milli kynja hefur ekki komið í ljós vegna cobicistats, emtricitabins eða tenofovir alafenamíðs.
English: HIV-1 RNA ≥ 50 copies/mL Virologic Failure Leading to Discontinuation Discontinued study drug due to other reasons and last available HIV-1 RNA ≥ 50 copies/mL
Icelandic: Veirufræðilegur brestur - leiðir til þess að meðferð er hætt Veirufræðilegur brestur - hætt af öðrum ástæðum og síðasta fyrirliggjandi gildi HIV-1
English: • emtricitabine, an anti-HIV medicine known as a nucleoside reverse transcriptase inhibitor
Icelandic: • emtricitabin, lyf sem tilheyrir flokki HIV lyfja sem kallast núkleósíðbakritahemlar
English: Opportunistic infections
Icelandic: Títantvíoxíð
English: Darunavir is an inhibitor of CYP3A, a weak inhibitor of CYP2D6 and an inhibitor of P-gp.
Icelandic: Darunavir er CYP3A hemill, vægur CYP2D6 hemill og P-gp hemill.
English: Increased monitoring for rifabutin associated adverse reactions including neutropenia and uveitis is warranted due to an expected increase in exposure to rifabutin.
Icelandic: Þörf er á auknu eftirliti með aukaverkunum tengdum rifabutini þ.m.t. daufkyrningafæð og æðahjúpsbólgu vegna þess að búast má við aukinni útsetningu fyrir rifabutini.
English: Symtuza should not be administered concomitantly with medicinal products containing tenofovir disoproxil (e.g. fumarate, phosphate, or succinate), lamivudine, or adefovir dipivoxil used for the treatment of HBV infection.
Icelandic: Ekki skal gefa Symtuza samhliða lyfjum sem innihalda tenofovir disoproxil (t.d. fumarat, fosfat eða succinat), lamivudin eða adefovir dipivoxil, sem notuð eru til meðferðar við HBV sýkingu.
English: Based on theoretical considerations, no clinically relevant interaction is expected.
Icelandic: Byggt á fræðilegum athugunum er ekki búist við neinum milliverkunum sem hafa klíníska þýðingu.
English: No adjustment of methadone dosage is expected when initiating co-administration with Symtuza.
Icelandic: Ekki er reiknað með að stilla þurfi skammt metadons af þegar samhliða notkun Symtuza hefst.
English: Based on theoretical considerations DRV/COBI is expected to increase salmeterol plasma concentrations.
Icelandic: Byggt á fræðilegum athugunum er búist við að DRV/COBI auki plasmaþéttni salmeterols.
English: The tablet core contains croscarmellose sodium, magnesium stearate, microcrystalline cellulose and colloidal silicon dioxide.
Icelandic: Töflukjarninn inniheldur natríum kroskarmellósa, magnesíumsterat, örkristallaðan sellulósa og kísiltvíoxíðkvoðu.
English: Based on theoretical considerations (systemic) dexamethasone is expected to decrease darunavir and/or cobicistat plasma concentrations.
Icelandic: Byggt á fræðilegum athugunum má búast við að (altækt) dexametason minnki plasmaþéttni darunavirs og/eða cobicistats.
English: The effects of Symtuza might be reduced if you take any of the following products.
Icelandic: Dregið getur úr áhrifum Symtuza ef eitthvað af eftirtöldum lyfjum er notað samhliða.
English: Emtricitabine triphosphate inhibits HIV replication through incorporation into viral DNA by the HIV reverse transcriptase (RT), which results in DNA chain-termination.
Icelandic: HIV með innleiðingu inn í veiru DNA fyrir tilstilli HIV bakrita (RT) og stöðvar þannig lengingu DNA keðjunnar.
English: Based on theoretical considerations DRV/COBI is expected to increase these PDE-5 inhibitor plasma concentrations.
Icelandic: Byggt á fræðilegum athugunum er búist við að DRV/COBI auki plasmaþéttni þessara PDE-5 hemla.
English: CORTICOSTEROIDS Budesonide
Icelandic: Budesonid Fluticason
English: Based on theoretical considerations DRV/COBI may alter warfarin plasma concentrations.
Icelandic: Byggt á fræðilegum athugunum má búast við að DRV/COBI breyti plasmaþéttni warfarins.
English: - Buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem, midazolam when used as an injection (medicines to treat trouble with sleeping or anxiety) - Metformin (to treat type 2 diabetes)
Icelandic: Buspiron, clorazepat, diazepam, estazolam, flurazepam, zolpidem, midazolam sem stungulyf
English: The below list of examples of drug drug interactions is not comprehensive and therefore the label of each drug that is co-administered with Symtuza should be consulted for information related to the route of metabolism, interaction pathways, potential risks, and specific actions to be taken with regards to co-administration.
Icelandic: Listinn hér á eftir sem inniheldur dæmi um lyfjamilliverkanir er ekki tæmandi og því skal fara yfir lyfjaupplýsingar fyrir hvert og eitt lyf sem er gefið samhliða Symtuza til að kynna sér umbrotsleiðir,
English: Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable, and these events can occur many months after initiation of treatment (see section 4.4).
Icelandic: Hins vegar er breytilegt hvenær þeir koma fram og geta slík tilfelli komið fram mörgum mánuðum eftir upphaf meðferðar (sjá kafla 4.4).
English: Concomitant use of Symtuza with lovastatin and simvastatin is contraindicated (see section 4.3).
Icelandic: Ekki má nota Symtuza samhliða lovastatini og simvastatini (sjá kafla 4.3).
English: Atorvastatin (10 mg once daily): atorvastatin AUC ↑ 290% atorvastatin Cmax ↑ 319% atorvastatin Cmin ND
Icelandic: Cmax ↑ 319% atorvastatin Cmin ND
English: No virologic data
Icelandic: Engin veirufræðileg gögn
English: ANTIPSYCHOTICS/NEUROLEPTICS Perphenazine
Icelandic: SEFANDI LYF/GEÐROFSLYF Perphenazin
English: However, tenofovir disoproxil reduced the viability index and weight of pups in a peri-postnatal toxicity study at maternally toxic doses.
Icelandic: Í eiturefnarannsóknum á tenofoviri disoproxil minnkuðu hins vegar lífslíkur og þyngd unga við og eftir fæðingu við skammta sem ollu eiturverkunum hjá móður.
English: Janssen-Cilag AB Tel: +46 8 626 50 00 jacse@its.jnj.com
Icelandic: +46 8 626 50 00 jacse@its.jnj.com
English: Common side effects (may affect up to 1 in 10 people)
Icelandic: Algengar aukaverkanir (geta komið fyrir hjá allt að 1 af hverjum 10 notendum)
English: Emtricitabine displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, and G (EC50 values ranged from 0.007 to 0.075 μM) and showed strain specific activity against HIV-2 (EC50 values ranged from 0.007 to 1.5 μM).
Icelandic: Gildi 50% hrifstyrks (EC50) emtricitabins voru á bilinu 0,0013 til 0,64 μM. Emtricitabin sýndi veiruhamlandi virkni gegn veirum í frumurækt gagnvart HIV-1 greinum A, B, C, D, E, F og G (EC50 gildi voru á bilinu 0,007 til 0,075 μM) og sýndi virkni sem var sérhæfð gegn HIV-2 (EC50 gildi voru á bilinu 0,007 til 1,5 μM) stofni.
English: Rifampicin to treat some infections such as tuberculosis Pimozide, lurasidone, quetiapine or sertindole to treat psychiatric conditions Ergot alkaloids like ergotamine, dihydroergotamine, ergometrine and methylergonovine to treat migraine headaches
Icelandic: Ergotalkalóíðar eins og ergotamin, dihydroergotamin, ergometrin og metýlergonovin við mígrenishöfuðverk
English: Rash is a common adverse drug reaction in patients treated with darunavir.
Icelandic: Útbrot eru algeng aukaverkun hjá sjúklingum sem fá meðferð með darunaviri.
English: • if you notice any symptoms of infection (e.g. swollen lymph nodes and fever).
Icelandic: ef vart verður einkenna sýkingar (t.d. bólgnir eitlar og hiti).
English: Non-clinical data on darunavir reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential.
Icelandic: Forklínískar upplýsingar um darunavir benda ekki til neinnar sérstakrar hættu fyrir menn, á grundvelli hefðbundinna rannsókna á lyfjafræðilegu öryggi, eiturverkunum eftir endurtekna skammta, eiturverkunum á erfðaefni, krabbameinsvaldandi áhrifum.
English: Emerging resistance in the Symtuza groups is shown in Table 4.
Icelandic: Nýframkomið ónæmi í Symtuza hópunum er sýnt í töflu
English: Based on theoretical considerations DRV/COBI may increase buprenorphine and/or norbuprenorphine plasma concentrations.
Icelandic: Byggt á fræðilegum athugunum má búast við að DRV/COBI auki plasmaþéttni buprenorphins og/eða norbuprenorphins.
English: However,the safety of components of Symtuza was evaluated through the clinical study TMC114-C230 (N = 12) for darunavir with ritonavir and GS-US-292-0106 (N = 50) for a fixed dose combination containing elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide.
Icelandic: Þó var öryggi innihaldsefna Symtuza metið með hliðsjón af klínísku rannsókninni TMC114-C230 (N = 12) fyrir darunavir ásamt ritonaviri og
English: Therefore, therapy with Symtuza should not be initiated during pregnancy, and women who become pregnant during therapy with Symtuza should be switched to an alternative regimen (see sections 4.4 and 4.6).
Icelandic: Því skal ekki hefja meðferð með Symtuza á meðgöngu og skipta skal yfir á aðra meðferð hjá konum sem verða þungaðar meðan á meðferð með Symtuza stendur (sjá kafla 4.4 og 4.6).
English: Following oral administration of Symtuza, the median terminal elimination half-life of emtricitabine is 17.2 hours.
Icelandic: Symtuza er miðgildi loka helmingunartíma brotthvarfs emtricitabins u.þ.b.
English: Based on theoretical considerations rifampicin is expected to decrease darunavir and/or cobicistat and/or tenofovir alafenamide plasma concentrations.
Icelandic: Byggt á fræðilegum athugunum má búast við að rifampicin minnki plasmaþéttni darunavirs og/eða cobicistats og/eða tenofovir alafenamíðs.
English: Concomitant use of PDE-5 inhibitors for the treatment of erectile dysfunction with Symtuza should be done with caution.
Icelandic: Gæta skal varúðar við samhliða notkun PDE-5 hemla til meðhöndlunar á ristruflunum samhliða Symtuza.
English: Therapy should be initiated by a physician experienced in the management of HIV-1 infection.
Icelandic: Læknir með reynslu af meðhöndlun HIV-1 sýkingar skal hefja meðferðina.
English: Uncommon side effects (may affect up to 1 in 100 people)
Icelandic: Sjaldgæfar aukaverkanir (geta komið fyrir hjá allt að 1 af hverjum 100 notendum)
English: C]-darunavir with ritonavir showed that approximately 7.7% of the administered dose of darunavir is excreted in the urine unchanged.
Icelandic: Niðurstöður úr rannsókn á jafnvægi milli skammta og útskilnaðar (mass balance study) með C]-darunaviri ásamt ritonaviri, sýndu að um það bil 7,7% af gefnum skammti darunavirs skiljast út í þvagi á óbreyttu formi.
English: Co-administration of Symtuza and these anticoagulants is not recommended.
Icelandic: Samhliða notkun Symtuza og þessara segavarnarlyfja er ekki ráðlögð.
English: Mean systemic emtricitabine exposure was higher in patients with severe renal impairment (eGFRCG < 30 mL/min) (33.7 mcg•h/mL) than in subjects with normal renal function (11.8 mcg•h/mL).
Icelandic: (33,7 míkróg•klst./ml) en hjá einstaklingum með eðlilega nýrnastarfsemi (11,8 míkróg•klst./ml).
English: Therefore, therapy with Symtuza should not be initiated during pregnancy, and women who become pregnant during therapy with Symtuza should be switched to an alternative regimen (see sections 4.2 and 4.6).
Icelandic: Því skal ekki hefja meðferð með Symtuza á meðgöngu og skipta skal yfir á aðra meðferð hjá konum sem verða þungaðar meðan á meðferð með Symtuza stendur (sjá kafla 4.2 og 4.6).
English: (P-gp inhibition)
Icelandic: (P-glýkóprótein hömlun)
English: No clinically relevant differences in cobicistat pharmacokinetics were observed between subjects with moderate impairment and healthy subjects.
Icelandic: Klínískt marktækur munur kom ekki fram á lyfjahvörfum cobicistats hjá einstaklingum með í meðallagi skerta lifrarstarfsemi og hjá heilbrigðum einstaklingum.
English: • if you have had problems with your kidneys.
Icelandic: • ef þú ert með sykursýki.
English: Therefore, therapy with Symtuza should not be initiated during pregnancy, and women who become pregnant during therapy with Symtuza should be switched to an alternative regimen (see sections 4.2 and 4.4).
Icelandic: Því skal ekki hefja meðferð með Symtuza á meðgöngu og skipta skal yfir á aðra meðferð hjá konum sem verða þungaðar meðan á meðferð með Symtuza stendur (sjá kafla 4.2 og 4.4).
English: Based on theoretical considerations DRV/COBI is expected to increase alfentanil plasma concentrations.
Icelandic: Byggt á fræðilegum athugunum er búist við að DRV/COBI auki plasmaþéttni alfentanils.
English: There are pharmacokinetic data for the (individual) components of Symtuza.
Icelandic: Upplýsingar um lyfjahvörf (hvers) innihaldsefna Symtuza liggja fyrir.
English: Systemic dexamethasone should be used with caution when combined with Symtuza.
Icelandic: Gæta skal varúðar við notkun dexametasons til altækrar verkunar samhliða Symtuza.
English: - Oestrogen-based hormonal contraceptives and hormone replacement therapy.
Icelandic: Getnaðarvarnarlyf með hormónum sem innihalda estrógen og uppbótarmeðferð með hormónum.
English: Co-administration of domperidone with Symtuza is contraindicated.
Icelandic: Ekki má nota domperidon samhliða Symtuza.
English: ANTIGOUT MEDICINES Colchicine
Icelandic: ÞVAGSÝRUGIGTARLYF Colchicin
English: In HIV infected patients treated with CART, immune reactivation syndrome has been reported.
Icelandic: Tilkynnt hefur verið um heilkenni endurvirkjunar ónæmis hjá HIV sýktum sjúklingum sem fá samsetta andretróveirumeðferð.
English: Difference in Proportions
Icelandic: Munur á hlutföllum
English: (CYP3A and/or P-gp induction).
Icelandic: (CYP3A og/eða P-glýkóprótein hömlun).
English: It is used in adults and adolescents aged 12 years and older who weigh at least 40 kg. Symtuza contains four active substances:
Icelandic: Það er notað hjá fullorðnum og unglingum 12 ára og eldri sem vega að minnsta kosti 40 kg.
English: Clinical monitoring is recommended when co-administering Symtuza with corticosteroids.
Icelandic: Klínískt eftirlit er ráðlagt þegar Symtuza er gefið samhliða barksterum.
English: Alternative anticonvulsants should be considered.
Icelandic: Íhuga skal notkun annars flogaveikilyfs.
English: Patients with pre-existing liver dysfunction, including chronic hepatitis B or C, have an increased risk for liver function abnormalities including severe and potentially fatal hepatic adverse reactions.
Icelandic: B eða C, eru í aukinni hættu á að truflun verði á lifrarstarfsemi, m.a. á verulegum og hugsanlega banvænum aukaverkunum á lifur.
English: Therefore, co-administration of Symtuza and sildenafil when used for the treatment of pulmonary arterial hypertension is contraindicated (see section 4.3).
Icelandic: Þess vegna má ekki nota sildenafil, til meðhöndlunar á lungnaslagæðaháþrýstingi, samhliða Symtuza (sjá kafla 4.3).
English: HIV-1 Treatment naïve Patients
Icelandic: Veirufræðilegur meðferðarbrestur HIV-1
English: In HIV infected patients with severe immune deficiency at the time of CART, an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.
Icelandic: Hjá HIV sýktum sjúklingum með alvarlegan ónæmisbrest við upphaf samsettrar andretróveirumeðferðar (CART) getur komið fram bólgusvörun vegna einkennalausra tækifærissýkinga eða leifa þeirra.
English: Virologic Response, % HIV-1 RNA < 50 copies/mL
Icelandic: RNA < 50 eintök/ml
English: ART-experienced patients
Icelandic: Sjúklingar með langvinna lifrarbólgu
English: Based on theoretical considerations DRV/COBI is expected to increase metformin plasma concentrations.
Icelandic: Byggt á fræðilegum athugunum er búist við að DRV/COBI auki plasmaþéttni metadons.
English: Liver problems that may occasionally be severe have been reported.
Icelandic: Látið lækninn vita ef einhver eftirtalinna aukaverkana kemur fram Greint hefur verið frá lifrarkvillum sem geta stundum verið alvarlegir.
English: (CYP3A and/or P-gp induction)
Icelandic: (CYP3A og/eða P-glýkóprótein virkjun)
English: Tenofovir alafenamide is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6 in vitro.
Icelandic: In vitro er tenofovir alafenamíð ekki hemill á CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 eða CYP2D6.
English: Based on theoretical considerations bosentan is expected to decrease darunavir and/or cobicistat plasma concentrations.
Icelandic: Byggt á fræðilegum athugunum má búast við að bosentan minnki plasmaþéttni darunavirs og/eða cobicistats.
English: Symtuza 800 mg/150 mg/200 mg/10 mg - film-coated tablets darunavir/cobicistat/emtricitabine/tenofovir alafenamide
Icelandic: Symtuza 800 mg/150 mg/200 mg/10 mg - filmuhúðaðar töflur darunavir/cobicistat/emtricitabin/tenofovir alafenamíð
English: Cobicistat is primarily metabolised and eliminated by the liver.
Icelandic: Umbrot og brotthvarf cobicistats fer aðallega fram í lifrinni.
English: Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets darunavir/cobicistat/emtricitabine/tenofovir alafenamide
Icelandic: Symtuza 800 mg/150 mg/200 mg/10 mg filmuhúðaðar töflur darunavir/cobicistat/emtricitabin/tenofovir alafenamíð
English: Based on theoretical considerations DRV/COBI is expected to increase colchicine plasma concentrations.
Icelandic: Byggt á fræðilegum athugunum er búist við að DRV/COBI auki plasmaþéttni colchicins.
English: CD4+ cell count mean change from baseline
Icelandic: Meðalgildi aukningar CD4+ frumutalningar frá grunngildi í viku
English: Symtuza with any of the following medicines'.
Icelandic: Symtuza við önnur lyf
English: 111-1921 x 10
Icelandic: 6 frumur/mm 3 (bil 111-1921 x 10
English: Symtuza and antacids can be used concomitantly without dose adjustment.
Icelandic: Nota má Symtuza og sýrubindandi lyf samhliða án þess að breyta skömmtum.
English: Based on theoretical considerations DRV/COBI is expected to increase these sedative/hypnotic plasma concentrations.
Icelandic: Byggt á fræðilegum athugunum er búist við að DRV/COBI auki plasmaþéttni þessara róandi lyfja/svefnlyfja.
English: Pharmacotherapeutic group: Antivirals for systemic use, antivirals for treatment of HIV infection, combinations ATC code: J05AR22
Icelandic: Veirulyf til altækrar notkunar, veirulyf til meðferðar á HIV sýkingum, blöndur, ATC-flokkur:
English: If a missed dose is noticed later than 12 hours of the time it is usually taken, it should not be taken and the patient should resume the usual dosing schedule.
Icelandic: frá venjubundnum tíma sem taka hefði átt skammtinn, á að sleppa honum og fylgja síðan venjulegri skammtaáætlun.
English: Co-administration of tadalafil for the treatment of pulmonary arterial hypertension with Symtuza is not recommended.
Icelandic: Ekki er ráðlagt að nota tadalafil til meðhöndlunar á lungnaslagæðaháþrýstingi, samhliða Symtuza.
English: No drug interaction trials have been performed using Symtuza.
Icelandic: Ekki hafa verið gerðar neinar rannsóknir á milliverkunum Symtuza.
English: Janssen-Cilag A/S Tlf: +45 45 94 82 82 jacdk@its.jnj.com
Icelandic: +45 4594 8282 jacdk@its.jnj.com
English: The combination of avanafil and Symtuza is contraindicated (see section 4.3).
Icelandic: Ekki má nota avanafil samhliða Symtuza (sjá kafla 4.3).